Investment Thesis
Propanc Biopharma is a pre-revenue clinical-stage biotech facing severe financial distress with only $443.7K in cash against a $4.1M annual burn rate, providing approximately 1-2 months of runway. The company exhibits classic pre-commercial biotech economics with no revenue generation and mounting operating losses of $14.7M, with no near-term path to profitability without substantial capital infusion or strategic partnership.
Strengths
- Minimal debt burden (0.01x debt-to-equity) reduces financial leverage risk
- Low long-term debt of only $55.0K provides flexibility for restructuring or financing
- Current ratio of 2.37x indicates assets are liquid, though absolute amounts are concerning
Risks
- Critical liquidity crisis: $443.7K cash against $4.1M annual operating burn creates imminent solvency risk with <2 months runway
- No revenue generation and no disclosed path to commercialization; company entirely dependent on R&D success and external funding
- Severe negative returns (ROE -145.4%, ROA -99.7%) and persistent operating losses of $14.7M indicate fundamental business model challenges
- Zero insider buying in last 90 days suggests lack of confidence from management in near-term prospects
Key Metrics to Watch
- Cash balance and monthly cash burn rate (critical for survival assessment)
- Success of clinical trials and regulatory milestones (required for de-risking valuation)
- Financing activities and capital raises (essential for extending runway)
Financial Metrics
Revenue
N/A
Net Income
-14.3M
EPS (Diluted)
$-0.95
Free Cash Flow
-4.1M
Total Assets
14.3M
Cash
443.7K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-145.4%
ROA
-99.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.37x
Quick Ratio
2.37x
Debt/Equity
0.01x
Debt/Assets
24.5%
Interest Coverage
-3,065.25x
Long-term Debt
55.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:05:09.520433 |
Data as of: 2026-03-31 |
Powered by Claude AI